243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620703
Title:
243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice.
Authors:
Delaloge, S; Conte, P; Im, S; Senkus-Konefka, E; Xu, B; Domchek, S; Masuda, N; Li, W; Tung, N; Armstrong, Anne C; Wu, W; Goessl, C; Runswick, S; Robson, M
Affiliation:
Breast Cancer Group, Institut Gustave Roussy, Villejuif, France
Citation:
243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. 2017, 28(suppl_5): Ann Oncol
Journal:
Annals of Oncology
Issue Date:
Sep-2017
URI:
http://hdl.handle.net/10541/620703
DOI:
10.1093/annonc/mdx365.006
Additional Links:
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.006/4108472/243PDOlympiAD-Further-efficacy-outcomes-in
Type:
Meetings and Proceedings
Language:
en
ISSN:
0923-7534; 1569-8041
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDelaloge, Sen
dc.contributor.authorConte, Pen
dc.contributor.authorIm, Sen
dc.contributor.authorSenkus-Konefka, Een
dc.contributor.authorXu, Ben
dc.contributor.authorDomchek, Sen
dc.contributor.authorMasuda, Nen
dc.contributor.authorLi, Wen
dc.contributor.authorTung, Nen
dc.contributor.authorArmstrong, Anne Cen
dc.contributor.authorWu, Wen
dc.contributor.authorGoessl, Cen
dc.contributor.authorRunswick, Sen
dc.contributor.authorRobson, Men
dc.date.accessioned2017-11-23T21:45:54Z-
dc.date.available2017-11-23T21:45:54Z-
dc.date.issued2017-09-
dc.identifier.citation243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534-
dc.identifier.issn1569-8041-
dc.identifier.doi10.1093/annonc/mdx365.006-
dc.identifier.urihttp://hdl.handle.net/10541/620703-
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.006/4108472/243PDOlympiAD-Further-efficacy-outcomes-inen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentBreast Cancer Group, Institut Gustave Roussy, Villejuif, Franceen
dc.identifier.journalAnnals of Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.